VEGFA and Hypertension: Although the simultaneous blockade of both VEGF-A and VEGFRs exhibited a further anti-tumor effect, previous phase I trials with combined usage of sunitinib and Bev demonstrated higher adverse event rates, including arterial adverse events, particularly cardiac and cerebral ischemia, venous adverse events, bleeding, and arterial hypertension for advanced solid cancers [6,8,9,25,34].